FDA warns GLP-1 drugs about eye condition

Statements (10)

1. ● Neutral

   The FDA in the United States identified a possible increase in the risk of rare eye disease for the Risco de perda de visão brand of weight-loss pens.

   infomoney.com.brNov 10, 2026 17:22 UTC
2. ● Neutral

   FDA adds rare vision-loss warning to GLP-1 drugs

   barchart.comNov 10, 2026 16:42 UTC
3. ● Neutral

   The FDA is warning that GLP-1 drugs carry a potential risk for an eye condition

   statnews.comNov 10, 2026 14:25 UTC
4. ● Neutral

   FDA requires warning labels on Ozempic and Wegovy due to risk of permanent vision loss

   foxbusiness.comNov 10, 2026 13:10 UTCHigh importance
5. ● Neutral

   The FDA requires all GLP-1 weight-loss drugs on the U.S. market to warn of a potential increased risk of an eye stroke.

   zerohedge.comNov 10, 2026 02:20 UTCHigh importance
6. ▼ Bearish

   FDA orders new vision loss warning for Ozempic and other GLP-1s

   gizmodo.comNov 9, 2026 21:46 UTCHigh importance
7. ● Neutral

   FDA adds rare vision-loss warning to GLP-1 drugs

   seattletimes.comNov 9, 2026 20:21 UTCHigh importance
8. ● Neutral

   The FDA ordered GLP-1 medication makers to add a warning about increased risk of vision loss on their drug labels.

   newser.comNov 9, 2026 20:03 UTC
9. ● Neutral

   FDA requires GLP-1 drugmakers to update product labels to warn of a rare eye condition that could lead to blindness.

   endpoints.newsNov 9, 2026 19:55 UTCHigh importance
10. ● Neutral

    FDA adds warning label to weight-loss drugs for eye condition

    bloomberg.comNov 9, 2026 14:53 UTC